Kornimate/medical-research-clean huggingface dataset:
functional and ultrasound guided resection of glioblastoma

Conditions: Glioma Glioblastoma Multiforme

Summary: functional and ultrasound-guided resection of glioblastoma: assessing the use of additional imaging during surgery to improve outcomes for patients with glioblastoma brain tumours

stage 1 (ideal iib study) of the trial is observational only and all participants will receive all technologies during surgery. stage 2 will be randomised. randomisation will be via the web-based service provided by the oxford clinical trials research unit (octru), using the method of minimisation. participants will be randomised 1:1 to either: 1. standard care surgery (neuronavigation based on preoperative imaging and intraoperative use of 5-ala)(control arm) 2. standard care surgery (neuronavigation based on preoperative imaging and intraoperative use of 5-ala) and of dti neuronavigation and nius (intervention arm) at baseline all participants will undergo a routine preoperative neuronavigation mri scan. those participants randomised to the experimental arm, will also have a dti scan (additional 5 minutes in the mri). all participants will then undergo the planned resection of their tumour, with the additional technologies if they are in the experimental arm. following surgery, participants in both arms have the same follow up schedule and undergo standard clinical care for a total of 24 months.

Eligibility criteria:
inclusion criteria: * age 18-70 years * neuro-oncology multi-disciplinary team (mdt) decision that the imaging shows a primary gb tumour which is maximally resectable (attempted gross total resection of all enhancing tumour) * patient is suitable for concomitant adjuvant radiotherapy and temozolomide (tmz) chemotherapy or adjuvant tmz at the time of mdt decision * able to receive 5-ala * willing and able to give informed consent * able to complete trial questionnaires, this may be with support where english is not their first language. (stage 2 only) * able to provide a proxy who is willing to complete questionnaires as requested (stage 2 only). exclusion criteria: * midline/basal ganglia/cerebellum/brainstem gb * multifocal gb * recurrent gb * suspected secondary gb * contraindication to mri

Keywords: dti ius
rhythm disturbances after ventricular septal defects

Conditions: Heart Block After Surgery

Summary: we would like to conduct a retrospective chart review examining the incidence of surgical heart block in children treated in the cardiac service line at children's healthcare of atlanta. we would like to look at the last 30 surgical heart block cases seen at children's healthcare of atlanta. we will collect the following information on each patient: patient date of birth date of the surgical procedure weight of the patient at the time of surgery concomitant diagnoses need for permanent pacemaker outcome of pacing (i.e. pacing successful) we hope to look at each data element in order to determine potential risks factors for surgical heart block. by identifying the risk factors, the investigator hopes to establish a training program regarding surgical avoidance of certain areas of the heart (if possible) and education regarding pacemaker follow-up. each patient will be given a unique study number. the patient's name, social security number, medical record number or initials will not be used in our research database.


Eligibility criteria:
inclusion criteria: patients with heart block after surgery - exclusion criteria: -

Keywords: arrhythmia pediatrics cardiac
guo's false lumen embolization : the first in man study of weflow-endoseal aorta vascular plug system

Conditions: Aortic Dissection Aneurysm

Summary: a prospective, single-center, first in man study to evaluate the safety and efficacy of weflow-endoseal aorta vascular plug system manufactured by hangzhou endonom medtech co., ltd. for the dissecting aneurysm of descending thoracic aorta after aortic dissection repair.


Eligibility criteria:
inclusion criteria: * patients aged 18 to 80 years old, no gender limitation; * the patient was diagnosed with a dissecting aneurysm of the descending thoracic aorta after the repair of the main artery dissection, and the treatment indications were one of the following: 1. aortic dissection aneurysm diameter ≥ 5.5cm 2. the diameter of descending thoracic aorta dissection increased rapidly ≥5 mm/ year 3. symptoms associated with dissection progression, such as chest and back pain * the diameter of false lumen approximately 1 cm superiorly to the celiac trunk ≤40 mm * appropriate anatomical conditions were assessed by imaging to allow the adjustable bend conveyor to enter the pseudolumen through tears of the iliac artery, subrenal aorta, or renal artery levels. * those who can understand the purpose of the trial, voluntarily participate in the study, sign the informed consent form by themselves or their legal representative, and are willing to complete the follow-up according to the protocol requirements. exclusion criteria: * aortic rupture; * continuous malperfusion of internal artery branches caused by dissection; * had previously received false lumen embolization; * proximal type i endoleak after aortic repair; * abdominal aortic dissection aneurysm diameter \> 5 cm * infectious aortic disease, arteritis, marfan syndrome (or other connective tissue diseases); * acute systemic infection; * history of myocardial infarction, tia or cerebral infarction within the past 3 months; * cardiac function grade iv (nyha rating) or lvef \< 30%; * hematological abnormalities: leukopenia (wbc \< 3×10\^9/l), anemia (hb \< 90 g/l); coagulation dysfunction, thrombocytopenia (plt count \< 50×10\^9/l); * renal insufficiency: serum creatinine \> 150 umol/l (or 3.0 mg/dl) and/or advanced kidney disease requiring renal dialysis, as determined by the investigator after thorough analysis; * severe liver insufficiency: alanine aminotransferase (alt) or aspartate aminotransferase (ast) exceeds the normal upper limit by 5 times; serum total bilirubin (stb) exceeded the normal upper limit by 2 times; * allergic to contrast agents, anesthetics, plugs, and delivery materials; * pregnant, breastfeeding or cannot contraception during the trial period; * participated in clinical trials of other drugs or devices during the same period; * life expectancy is less than 12 months (such as advanced malignant tumors); * investigator judged that not suitable for interventional treatment.
effect of low-level laser therapy following direct pulp capping on postoperative sensitivity by thermal stimulus

Conditions: Low-level Laser Therapy

Summary: the aim of this study was to investigate the effect of low-level laser therapy (lllt) on postoperative pain provoked by thermal stimulation in direct pulp capping. all the patients who received consent form in this retrospective study were retrieved from the records of patients attended for routine dental treatment at the ordu university, faculty of dentistry, department of endodontics between 01.10.2017-01.10.2018. study subjects were recruited from the pool of patients who performed direct pulp capping by a single operator. a total of 123 pre-treated teeth of 123 patients who referred to ordu university, faculty of dentistry were examined. follow-up examinations were carried out at postoperative 6th hours, 1st and 7th days with visual analog scale (vas), and treatment outcome were assessed. participants were allocated to the laser and control group which consist of 42 patients in each group. 6 patients were excluded from the study due to missing data in both groups. thus, data from 72 patients who had been carried out direct pulp capping were assessed.


Eligibility criteria:
inclusion criteria: 1. mandibular and maxillary permanent molars with pulpal exposure between 0.5-1.0 mm 2. periodontally healthy teeth (no more than 3mm probing depth) 3. pulpal exposure occurring only on the occlusal side of the tooth 4. systemically healthy participant 5. participants who signed the written consent form 6. patients aged 15-45 7. patients who have not used analgesic or antibiotic in the past two weeks 8. patients whose data are fully and accurately recorded 9. patients who do not use immunosuppressive drugs and do not need antibiotic prophylaxis exclusion criteria: 1. patients who need a second anesthetic 2. presence of a previous restoration of the tooth 3. patients using psychiatric or sedative medication 4. patients who had a direct pulp capping treatment on several teeth 5. patients with tooth pain and unable to localize this pain 6. patients taking pain medication within 1 week after the procedures 7. patients with a lack of data during follow-up 8. treated teeth without following clinical procedures

Keywords: direct pulp capping low level laser therapy thermal stimulus biostimulation
comparative study of oestradiol suppression: zoladex 10.8mg/3 month vs. 3.6mg/month in er +ve ebc pre-menopausal patients

Conditions: Breast Cancer

Summary: the primary purpose of this study is to establish if a 10.8 mg dose of zoladex given 3 monthly is non-inferior to a 3.6 mg dose of zoladex given monthly in terms of oestradiol suppression in patients with oestrogen receptor positive early breast cancer.


Eligibility criteria:
inclusion criteria: * pre-menopausal women aged 20 years or over with histological/cytologically-confirmed er +ve breast cancer who have undergone radical surgery and who performance status 0,1 or 2. exclusion criteria: * evidence of metastatic disease, previous bilateral oophorectomy or radiotherapy to the ovaries, previous chemotherapy, breast surgery completed over 12 weeks before starting trial treatment, previous neo-adjuvant/adjuvant hormonal breast cancer therapy
efficacy and safety of combined thread embedding acupuncture with auricular acupuncture for gerd

Conditions: GERD

Summary: gastroesophageal reflux disease (gerd) is increasingly prevalent today. proton-pump inhibitors (ppis) are the primary treatment, yet their effectiveness remains limited. various acupuncture methods have shown promise in treating gerd. among these, thread embedding acupuncture (tea) and auricular acupuncture (aa) offer the advantage of prolonged treatment per intervention, significantly reducing healthcare visits for procedures, particularly beneficial for conditions requiring extended therapy. this has led to the widespread application of tea and aa in gerd treatment. however, evidence supporting their effectiveness remains inconclusive. in this study, we aim to assess the efficacy and safety of combining tea with aa for treating gerd. according to traditional medicine, treatment should be pattern-based. thus, we will focus on patients exhibiting the liver qi invading stomach pattern, as reports indicate its prevalence among gerd patients.

patients with gerd diagnosed through the gerdq score and presenting the traditional medicine pattern of liver qi invading stomach, meeting the inclusion and not the exclusion criteria, will be included in the study. upon randomization, participants will be allocated into two groups: the control and intervention groups. the study spans four weeks. both groups will receive standard gerd treatment following current guidelines, which include ppis, additional antacids as required, and lifestyle modifications. the intervention group will receive an additional combination of thread embedding acupuncture therapy (tea) every other week and auricular acupuncture (aa) weekly. patients will undergo weekly follow-up examinations. symptom assessment, quality of life evaluations using specific questionnaires, and antacid medication usage will be monitored weekly. adverse effects (ae) related to the treatment will be documented throughout the trial.

Eligibility criteria:
inclusion criteria: * men or women aged from 18 to 60 years * gerdq score of eight or higher * having heartburn and/or regurgitation on two days per week or more * diagnosis of gerd with liver qi invading stomach pattern exclusion criteria: * any prior endoscopy-confirmed structural diseases * uncontrolled inflammatory bowel disease, chronic or genetic conditions, alcohol or drug abuse history * alarming symptoms indicating gastric cancer, complicated ulcers, or serious illnesses * history of esophageal or gastrointestinal surgery * current use of medications impacting gerd treatment or assessment * recent (within two weeks) western medicine or traditional medicine treatment for gerd * history of hypersensitivity reactions to any components involved in the intervention * pregnancy or breastfeeding * current participation in any other clinical trials
endoscopic myotomy of the pylorus to improve emptying and symptoms trial

Conditions: Gastroparesis

Summary: a randomized clinical trial comparing endoscopic per-oral pyloromyotomy (pop) versus a control sham intervention (diagnostic esophagogastroduodenoscopy (egd) without pyloric disruption) in patients with medically refractory gastroparesis.

a comparative effectiveness, single center (with two surgical units), randomized (1:1) study of endoscopic per-oral pyloromyotomy (pop) versus a control sham intervention (diagnostic esophagogastroduodenoscopy (egd) without pyloric disruption) in adult patients with medically refractory gastroparesis who have failed management with dietary, lifestyle, and pharmacological therapy for at least six months.

Eligibility criteria:
inclusion criteria: 1. male or female, aged 18-75 2. diagnosis of medically refractory gastroparesis by 4 hour non-extrapolated solid phase gastric emptying study completed within 12 months of enrollment. medical refractoriness is defined by at least 6 months of medical treatment with no significant improvement in baseline symptoms 3. completion of all routine assessments in our multidisciplinary gastroparesis clinic, which includes evaluation by gastroenterology, behavioral health, and nutrition specialists 4. ability to take oral medication and be willing to adhere to the post-procedure dietary and medication regimen 5. for females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation 6. stated willingness to comply with all study procedures and availability for the duration of the study 7. willingness and reasonable expectation that the individual will be able to travel to the study site for the intervention and each scheduled in-person assessment, as well as virtual assessments if necessary 8. be able to speak and read the english language. exclusion criteria: 1. active use of narcotic pain medication 2. presence of concomitant gastrointestinal transit disorder such as small bowel dysmotility or uncontrolled colonic dysmotility (as defined by clinical judgement or \< 3 bowel movements per week) 3. etiology of gastroparesis is post-surgical 4. pregnancy or lactation 5. history of egg allergy 6. prior surgical intervention of the stomach or gastric pylorus 7. current parenteral nutrition 8. uncontrolled coagulopathy (platelet count \ 1.5) or use of anticoagulant medications (with the exception of antiplatelet therapy)
bipolar enbloc versus thulium-yag enbloc resection of bladder tumors

Conditions: Bladder Cancer

Summary: prospective controlled study randomized comparing bipolar enbloc versus thulium enbloc for bladder tumours

bladder cancer is the ninth most prevalent cancer worldwide and the 2nd most common urologic cancer in the last two decades after cancer prostate . most bladder cancers attributed to exposure to environmental and occupational chemicals, the largest of which by far is tobacco smoke. greater tobacco smoke and occupational exposure in men may help in the explanation of the 4-fold gender difference in bladder cancer incidence . approximately 75-85% of patients with bladder cancer present with disease confined to the mucosa or submucosa , which is referred to as nonmuscle invasive bladder cancer (nmibc). transurethral resection of bladder tumor (turbt) is still considered the gold standard treatment for primary nonmuscle invasive bladder cancer. there are many drawbacks for conventional turbt procedure such as such as the deficiency of the bladder detrusor muscle in the specimen , the obturator jerk, thermal damage to surrounding tissues, and the technique of( incise and scatter). these drawbacks may lead to difficulty in performing an accurate pathological evaluation of fragment tissue and increase the risk of recurrence. laser therapy for bladder cancer was first reported in germany in the 1970s and was approved to clinical use in the usa in 1984. modern laser technology has led to new alternatives to conventional transurethral resection of bladder tumor (turbt) due to its efficacy and good control of bleeding. with the introduction of en-bloc resection of urinary bladder tumors, laser come back into focus. the two most commonly used lasers at present are thulium and holmium laser. in 2018 pa geavlete, declared that the enbloc bipolar resection of bladder tumors using mushroom loop provide the advantages of superior surgical safety, decreased perioperative morbidity and faster postoperative recovery, when compared to the standard monopolar turbt but showed no superiority in oncological outcome.

Eligibility criteria:
* inclusion criteria: 1. patients with nmibc 2. bladder tumors\<4 cm in ct. 3. resectable bladder tumors. 4. age \<80 years. * exclusion criteria : 1. bladder tumours \> 4cm . 2. metastatic bladder tumors. 3. patients with carcinoma in situ cis . 4. patients with coagulopathies. 5. domal bladder tumors.
the combination therapy with ra-223 and enzalutamide

Conditions: Castration-resistant Prostate Cancer; Bone Metastases

Summary: this study is to evaluate preliminary efficacy of ra-223 in combination with enzalutamide in progressive crpc patients with bone metastasis


Eligibility criteria:
inclusion criteria: 1. patients diagnosed as crpc 2. surgical or those who will be treated with luteinizing hormone-releasing hormone (lhrh) agonists throughout the study period, 3. patients who had \>30% of psa response to enzalutamide prior to enrollment, 4. interval between psa progression and enrollment is up to 3 months, 5. with bone metastases (≥ 2 hot spots) on bone scintigraphy within previous 24 weeks, 6. no intention to use anti-cancer chemotherapy within the next 6 months, 7. eastern cooperative oncology group performance status (ecog-ps): 0-1, 8. life expectancy ≥ 6 months, 9. laboratory requirements within 30 days before enrollment: * absolute neutrophil count (anc) ≥ 1.5 x 10e9/l, * platelet count ≥ 100 x 10e9/l, * hemoglobin ≥ 10.0 g/dl, * total bilirubin level ≤1.5 institutional upper limit of normal (uln), * aspartate aminotransferase (ast) and alanine aminotransferase (alt) ≤ 2.5 uln, * creatinine ≤ 1.5uln, and estimated glomerular filtration rate (gfr) ≥ 30 ml/min/1.73 m2, 10. age ≥ 20, 11. ability to understand and the willingness to sign a written informed consent (ic). exclusion criteria: 1. prior chemotherapy or planned treatment with chemotherapy, 2. psa progression within 3 months after initiation of enzalutamide 3. prior treatment with corticosteroids, estramustine or abiraterone acetate, 4. any systemic radiotherapy with strontium-89, samarium-153, rhenium-186 or rhenium-188 for the treatment of bone metastases, 5. had history of gastrointestinal bleeding or ulcer within 3 months prior to study entry, 6. history of visceral metastasis, or presence of visceral metastasis detected by screening imaging examinations, 7. history of or known brain metastasis, 8. malignant lymphadenopathy ≧1.5 cm in short axis, 9. imminent or established spinal cord compression based on clinical findings and/or mri (magnetic resonance imaging), 10. any other serious illness or medical condition 11. substance abuse, medical, psychological, or social conditions that might interfere with the subject's participation in the study or evaluation of the study results 12. those who judged to be inappropriate by the principal investigator or co-investigator.

Keywords: castration-resistant prostate cancer bone metastasis
injury epidemiology within scottish professional football

Conditions: Injury;Sports

Summary: the aim of the present study is to establish the injury incidence, severity and burden typically observed within scottish professional football clubs. in line with the well-established model of sports injury prevention research proffered by van mechelen, the first stage in this process is establishing the extent of the problem i.e. injury incidence, severity and burden. such a multi-club study has never been conducted within scotland despite a thriving professional game.


Eligibility criteria:
inclusion criteria: * professional football player contracted to an spfl club exclusion criteria: * loss of professional status as a footballer

Keywords: association football soccer injury epidemiology
second primary cancer and early-onset colorectal cancer

Conditions: Colorectal Cancer; Second Primary Cancer

Summary: the objective of this study was to analyze the pathological factors influencing the occurrence and prognosis of spc in crc patients of varying ages and compare the differences in the patterns of spc occurrence and prognosis among patients of different age groups.


Eligibility criteria:
inclusion criteria: * patients undergoing radical surgery for colorectal cancer at fudan university shanghai cancer center between january 2008 and december 2018. * stage ⅰ-ⅳ colorectal cancer confirmed by clear pathological information exclusion criteria: * previous history of other cancers before surgery * patients under 18 years old or over 80 years old
visanne study to assess safety in adolescents

Conditions: Endometriosis

Summary: a clinical trial which was designed to demonstrate the safety and efficacy of visanne (approved in endometriosis for adults) in the adolescent population.


Eligibility criteria:
inclusion criteria: * female adolescents after menarche (12 - less than 18 years of age) at screening. for finland: adolescents aged 12 - 14 years old who present with clinical features of endometriosis will only be enrolled into the study if their diagnosis of endometriosis has been confirmed by laparoscopy. * dysmenorrhea of at least moderate intensity, with or without chronic pelvic pain, for at least 2 cycles in the previous 4 months and one of the following conditions: * clinically suspected endometriosis based on the presence of pelvic pain incompletely relieved by non steroidal anti-inflammatory drugs and/or oral contraceptives * any abdominal pain associated with ultrasound findings suggestive of endometriosis (abdominal, vaginal or rectal; only after additional specific consent and assent) * failure of surgical treatment for endometriosis (with cyclic or chronic pelvic pain of at least 4 months duration postsurgery) * threshold for endometriosis-associated pelvic pain (eapp) score: at least 30 on a 100 units visual analog scale retrospectively evaluated at screening for the last 4 weeks exclusion criteria: * absence of endometriosis at laparoscopy * previous application of hormonal agents including oral contraceptives within 2 months, progestins, danazol within 3 months, and gonadotropin releasing hormone (gnrh) agonists within 6 months prior to start of treatment * chronic pelvic pain that might be related to genitourinary disease or to chronic or recurrent gastrointestinal disease, including irritable bowel syndrome (defined as a disease characterized by pain relieved by defecation and irregular defecation patterns lasting at least 3 months) * clinically established need for primary surgical treatment of endometriosis

Keywords: endometriosis dexa adolescent safety efficacy post-menarche